Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07670078
Starting soon Not applicable

Comparıson of Analgesıc Effıcacy of Dıfferent Volumes of Serratus Posterior Superıor Intercostal Plane Block After Modıfıed Radıcal Mastectomy Surgery

NCT07670078 · tracked via the Priya Life Science Turkey tracker
Sponsor
Cumhuriyet University
Phase
Not applicable
Started
2026-08-25
Last updated
2026-08-25

Condition(s) studied

Modified Radical MastectomyPost Operative Pain, AcuteFacial Plane Blocks

Investigational drug(s) / intervention(s)

Serratus Posterior Superior Intercostal Plane (SPSIP) block 40 ml of 0.1875% bupivacaineSerratus Posterior Superior Intercostal Plane (SPSIP) 50 ml of 0.15% bupivacaineSerratus Posterior Superior Intercostal Plane (SPSIP) 30 ml of 0.25% bupivacaine

Serratus Posterior Superior Intercostal Plane (SPSIP) block 40 ml of 0.1875% bupivacaine: A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 40 ml of 0.1875% bupivacaine (15 ml of the drug + 25 ml of isotonic solution).

Serratus Posterior Superior Intercostal Plane (SPSIP) 50 ml of 0.15% bupivacaine: A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 50 ml of 0.15% bupivacaine (15 ml of the drug + 35 ml of isotonic solution).

Serratus Posterior Superior Intercostal Plane (SPSIP) 30 ml of 0.25% bupivacaine: A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 30 ml of 0.25% bupivacaine (15 ml of the drug + 15 ml of isotonic solution).

Study summary

The aim of researchers is to compare the effects of three different local anesthetic concentrations and volumes on opioid consumption, postoperative analgesic efficacy, and pain scores during ultrasound-guided SPSIP blocks in patients undergoing modified radical mastectomy. Additionally, we aim to map and identify the dermatomal areas where different concentrations and volumes of SPSIP blocks provide analgesia.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * The study included adult patients over 18 years of age who underwent modified radical mastectomy under general anesthesia and were classified in risk groups I-II-III according to the American Society of Anesthesiologists (ASA) risk classification. Exclusion Criteria: * patients with coagulopathy, * patients with signs of infection at the block application site, * patients with ASA IV * patients with known allergies to any of the study drugs, * patients with ineffective block * patients who could not cooperate during postoperative pain assessment * patients who wanted to withdraw from the study, * patients with alcohol and drug addiction, * patients with musculoskeletal abnormalities * patients with kidney and liver failure * patients with obesity (body mass ≥ 35 kg/m2)

Primary outcome measure(s)

  • Total tramadol consumption — Postoperative 24 hours
    Postoperative total analgesic need was recorded as "milligram" in unit.

Trial sites (1)

FacilityCityRegionStatus
Sivas Cumhuriyet University Sivas Sivas

More Cumhuriyet University trials in Turkey

S-TAP vs RSB in Midline Abdominal Incision Laparotomy Active, not recruiting
The Effect of Mandala Art Therapy, Psychological Resilience, Coping With Cancer, Colorectal Cancer Surgery Recruiting
Comprasion of SPSIP and Rhomboid Intercostal Plan Blocks on VATS Recruiting
ARCS-Based Training to Improve Nursing Students' Communication, Motivation, and Self-Efficacy Recruiting
Analgesic Effect of M-TAPA and TAPB on Laparoscopic Cholesistectomy Recruiting

Other trials for the same condition

Intraoperative Ketamine for Chronic Postoperative Pain After Open-Heart Surgery Starting soon
Serratus Posterior Superior Plane Block for Postoperative Pain in Cardiac Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07670078 on ClinicalTrials.gov ↗ ← All trials in Turkey